Search research articles
Contact Us
Filters
Showing results (41-50 of 73) with videos related to
Page
of 8
Sort By:
Annals of Neurology
|
February 22, 2026
Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy
Karlien Mul, Michael P McDermott, Russell J Butterfield, et al.
NPJ Genomic Medicine
|
August 16, 2018
Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy
Betsy E P Ostrander, Russell J Butterfield, Brent S Pedersen, et al.
Muscle & Nerve
|
April 25, 2020
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic
Aravindhan Veerapandiyan, Kathryn R Wagner, Susan Apkon, et al.
Journal of Neuromuscular Diseases
|
April 12, 2024
Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
Craig M Zaidman, Natalie L Goedeker, Amal A Aqul, et al.
Nature Genetics
|
July 16, 2021
p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models
Edward J Grow, Bradley D Weaver, Christina M Smith, et al.
BMC Neurology
|
September 12, 2019
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
Samantha LoRusso, Nicholas E Johnson, Michael P McDermott, et al.
Journal of Neurology
|
April 9, 2022
Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab
Sarah P Sherlock, Jeffrey Palmer, Kathryn R Wagner, et al.
Neurology
|
March 21, 2014
Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis
Russell J Butterfield, Tamara J Stevenson, Lingyan Xing, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 30, 2025
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy
Barry J Byrne, Russell J Butterfield, Perry B Shieh, et al.
Journal of Neuromuscular Diseases
|
March 13, 2023
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
Richard S Finkel, Basil T Darras, Jerry R Mendell, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 73) with videos related to
Sort By:
Page
of 8
Annals of Neurology
|
February 22, 2026
Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy
Karlien Mul, Michael P McDermott, Russell J Butterfield, et al.
NPJ Genomic Medicine
|
August 16, 2018
Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy
Betsy E P Ostrander, Russell J Butterfield, Brent S Pedersen, et al.
Muscle & Nerve
|
April 25, 2020
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemic
Aravindhan Veerapandiyan, Kathryn R Wagner, Susan Apkon, et al.
Journal of Neuromuscular Diseases
|
April 12, 2024
Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy
Craig M Zaidman, Natalie L Goedeker, Amal A Aqul, et al.
Nature Genetics
|
July 16, 2021
p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models
Edward J Grow, Bradley D Weaver, Christina M Smith, et al.
BMC Neurology
|
September 12, 2019
Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study
Samantha LoRusso, Nicholas E Johnson, Michael P McDermott, et al.
Journal of Neurology
|
April 9, 2022
Quantitative magnetic resonance imaging measures as biomarkers of disease progression in boys with Duchenne muscular dystrophy: a phase 2 trial of domagrozumab
Sarah P Sherlock, Jeffrey Palmer, Kathryn R Wagner, et al.
Neurology
|
March 21, 2014
Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis
Russell J Butterfield, Tamara J Stevenson, Lingyan Xing, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
June 30, 2025
Complement activation in a phase Ib study of fordadistrogene movaparvovec for Duchenne muscular dystrophy
Barry J Byrne, Russell J Butterfield, Perry B Shieh, et al.
Journal of Neuromuscular Diseases
|
March 13, 2023
Intrathecal Onasemnogene Abeparvovec for Sitting, Nonambulatory Patients with Spinal Muscular Atrophy: Phase I Ascending-Dose Study (STRONG)
Richard S Finkel, Basil T Darras, Jerry R Mendell, et al.
Page
of 8